60. A compound of the general formula

R-NH-HAEGTFTSDVSSYLEGQAAKEFIAWLVK-$CONH_2$ (SEQ ID NO:1)

wherein R = H or an organic compound having from 1-10 carbon atoms.

61. The compound according to claim 60, wherein R is a carboxylic acid moiety.

62. The compound according to claim 61, wherein R is formyl-, acetyl-, propionyl-, isopropionyl-, methyl-, ethyl-, propyl-, isopropyl-, –butyl-n, sec-butyl-, or tert-butyl-.

B2

63. The compound according to claim 60, wherein the compound exists in a phosphorylated, acetylated, and/or glycosylated form.

64. A method of using a pharmaceutical composition containing a compound according to claim 60, comprising administering the composition to a person for the treatment of insulin-dependent diabetes mellitus, insulin-independent diabetes mellitus, MODY (maturity-onset diabetes in young people), secondary hyperglycaemia in connection with a pancreatic disease or endocrine disease or induced by a drug, pathologic glucose tolerance, hyperglycaemia, dyslipoproteinaemia, obesity, hyperlipoproteinaemia, or hypotonia.

65. The method of claim 64, wherein the pancreatic disease is chronic pancreatitis, pancreatectomy, or haemochromatosis, the endocrine disease is acromegaly, Cushing's syndrome, phaeochromocytoma, or hyperthyerosis and the drug is a benzathiadiazine salidiuretic, diazoxide, or a glucocorticoid.

66. The method according to claim 64, in a release form by which the release is attained in a long-lasting or pulsatile manner.

B2

67. The method according to claim 64, suitable for subcutaneous, intravenous, peroral, intramuscular, or transpulmonary administration.

68. A composition for human administration comprising the compound according to claim 60, in combination with a physiologically acceptable carrier or diluent.

69. The composition according to claim 68, in a release form by which release of the compound is attained in a long-lasting or pulsatile manner.

70. The composition according to claim 68, suitable for subcutaneous, intravenous, or intramuscular administration.

71. The composition according to claim 68, suitable for peroral administration.

72. The composition according to claim 68, suitable for transpulmonary administration.

73. A composition comprising a therapeutically effective amount of the compound according to claim 61, in combination with a pharmaceutically acceptable carrier or diluent.

B2 74. The composition according to claim 73, in a release form by which release of the compound is attained in a long-lasting or pulsatile manner.

75. The composition according to claim 73, suitable for subcutaneous, intravenous, or intramuscular administration.

76. The composition according to claim 73, suitable for peroral administration.

77. The composition according to claim 73, suitable for transpulmonary administration.

REMARKS

The specification is amended, hereby, to insert a sequence identifier adjacent the corresponding sequence.